At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of Radiation, Avastin and Tarceva for Resectable or Locally Advanced Pancreatic Adenocarcinoma
In Brief
A Phase 1 clinical trial evaluating Avastin, Tarceva, and 1 other intervention for Pancreatic Cancer. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy for carcinoma of the pancreas. An additional primary objective is to describe the frequency and nature of grade III/IV and grade I/II toxicities associated with this regimen. Secondary objectives include describing 1-year disease-free survival and overall survival rates as well as to estimate clinical and pathologic complete response rates associated with this regimen.
Study Details
Timeline
Interventions
Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
Radiation to the pancreas Monday through Friday for 28 treatments